Phosphorothioated amino-AS1411 aptamer functionalized stealth nanoliposome accelerates bio-therapeutic threshold of apigenin in neoplastic rat liver: a mechanistic approach

Table 1 Plasma and liver pharmacokinetic parameters in the HCC rats treated with NLCs/PEG-NLCs/Apt-NLCs and free apigenin as iv bolus form through tail vain

		Api	NLCs	PEG-NLCs	Apt-NLCs
In vivo plasma pharmacokinetic data	Cmax (ng/ml)	15.5 ± 0.16	17.2 ± 1.13	18.1 ± 0.55	19.2 ± 0.51
	AUC last (ng/h/ml)	125.8 ± 52	496.4 ± 62.9	826.4 ± 53^#	986.2 ± 47^#
	AUMC	1608 ± 1419	15,290 ± 3089	30,457 ± 2350	37,988 ± 1994
	MRT (h)	12.81 ± 1.58	30.83 ± 1.09	36.94 ± 0.41^$	38.91 ± 0.21^$
	AUC 0-∞ (ng h/ml)	130.61 ± 53.4	539.64 ± 79.34	1072.47 ± 171.21*	1446.21 ± 182.65*
	t_1/2 (h)	5.25 ± 0.25	13.51 ± 0.2	39.02 ± 0.2	43.02 ± 0.25
	Clearance (L/h/Kg)	15.9 ± 0.55	4.03 ± 0.63	2.42 ± 0.66	2.03 ± 0.52
In vivo liver pharmacokinetic data	Cmax (ng/ml)	160 ± 7.87	165.7 ± 7.37	178.9 ± 8.14	223.4 ± 6.64
	Tmax (h)	1 ± 0.15	3 ± 0.2	6 ± 0.22	6 ± 0.26
	AUC last (ng.h/ml)	1828 ± 194	4336 ± 474	9410 ± 553	14,658 ± 592
	AUMC	25,535 ± 3589	119,549 ± 17,352	330,328 ± 2126*	582,753 ± 21,258*
	MRT (h)	13.2 ± 3.8	27.55 ± 6.1	35.48 ± 5.9	42 ± 4.6
	AUC 0-∞ (ng.h/ml)	1898 ± 197	6440 ± 542	8961 ± 705	12,955 ± 892
	T1/2 (h)	5.65 ± 0.52	16 ± 1.2	34 ± 2	50 ± 1.45
	Clearance (L/h/Kg)	1.01 ± 0.01	0.461 ± 0.033	0.213 ± 0.006^	0.136 ± 0.005^

Data from the three independent experiments denote mean ± standard deviation (n = 3)
^{#, $}Indicated significant (p < 0.05) improvement in AUC and MRT values in plasma for Apt-NLCs/PEG-NLCs treated animals in comparison to NLCs. (*) Indicated significant (p < 0.05) improvement in AUC in liver values in Apt-NLCs/PEG-NLCs treated animals in comparison to NLCs. ^ indicated significant (p < 0.05) reduction in hepatic clearance in Apt-NLCs/PEG-NLCs treated animals in comparison to NLCs

ISSN: 1477-3155